iHeart Japan Co. plans for clinical trials on cardiac insuffiency treatment by iPS cells within 4 years
The venture company, originating from Kyoto’s CIRA, was established on April 18, 2013 iHeart Japan, https://iheartjapan.jp/
The venture company, originating from Kyoto’s CIRA, was established on April 18, 2013 iHeart Japan, https://iheartjapan.jp/
First topic is the development of a simple test for infectious diseases for Asian needs. Arkray will dispatch a researcher to IBN for this project. Arkray press release, May 22, 2013
The reactor provides 50 L/d of biodiesel from waste oil and methanol mixed at a molar ration of 3:1. Quality is close to ASTM D6751 standards. China Chemical News, May 22, 2013
Bacteria under study will be Lactobacillus casei and Bifidobacterium breve whose metabolites, lactic and acetic acid, are believed to control the cell cycle of the intestinal epithelium. Preliminary experiments at Pasteur Institute were done using co-cultivation of m-ICcl2 mouse epithelial cells with L. casei or B. breve, under a grant from the European Science Foundation […]
Blockbuster is Vesicare (Solifenacin-succinate), a muscarine receptor blocker for the treatment of overactive bladder Astellas news release, May 13, 2013
The products SMZ25 and SMZ18 have world’s largest zoom range and highest resolution. Nikon press release, May 15, 2013
The tripeptide L-gamma-Glu-L-Val-Gly has a 10fold higher umami “richness” feeling as compared to glutathione. It acts as an agonist to the G-protein conjugation-type receptor (GPCR). Synthesis is from L-valyl-glycine by gamma-glutamyl transferase (GGT). JSBBA Annual Meeting 2013, Sendai, Symposium LS8, March 26
The most important product is eribulin (Halaven), a fully synthetic macrocyclic ketone analogue of the marine sponge natural product halichondrin B. Aricept, another antitumor compound of Eisai, lost patent protection last year and shows reduction in sales. Eisai press release, May 13, 2013
Among several items, Astellas will establish an Innovation Management (AIM) and scale back US subsidiaries, including refocusing of Astellas US Research Institute and closure of OSI Pharmaceuticals and Perseid Therapeutics. In-house fermentation research will be stopped, and the Kashima facility in Osaka will be closed (scheduled during FY2015). Multiple functions of the Kashima facility will […]
The fish-meat and -cartilage derived components will be blended with quercetin, polyphenols, vitamin D and other health-food products. Suntory news release, May 13, 2013